Clinical reference Biomarker Directory
Back to directory

Anti-beta2 glycoprotein1

Established

Anti-β2GP1 is one of three antibodies used to classify antiphospholipid syndrome.

Also known as Anti-β2GP1 anti-beta-2-glycoprotein I antibody
In plain language

This antibody is one of three tested together to diagnose antiphospholipid syndrome, a condition that raises the risk of blood clots and pregnancy complications. Newer diagnostic criteria from 2023 changed exactly how these antibody results are weighed.

Biomarker & context

Anti-beta2 glycoprotein-1 (anti-β2GP1) is one of three antiphospholipid antibodies used to diagnose antiphospholipid syndrome (APS), an autoimmune clotting disorder associated with recurrent thrombosis and pregnancy loss.

What it indicates

Positive anti-β2GP1 (IgG, IgM, or IgA), alongside anticardiolipin antibodies and lupus anticoagulant, contributes to APS classification when paired with a clinical event (thrombosis or defined pregnancy morbidity).

Diagnosis & clinical testing

Measured via ELISA; the 2023 ACR/EULAR APS classification criteria substantially revised how these three antibodies and their titers are weighted, changing diagnostic rates in some populations, including recurrent pregnancy loss patients.

Guiding treatment

Confirmed APS with anti-β2GP1 positivity typically guides long-term anticoagulation decisions, particularly for patients with prior thrombosis; isolated positivity without a clinical event does not by itself warrant treatment.

Clinical significance

Part of the 2023-revised APS classification criteria; requires a clinical event to establish diagnosis.

References
  1. 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.
  2. Prevalence of Antiphospholipid Antibody Syndrome Among Patients with Recurrent Pregnancy Loss. (2024). PMC.